NORATEST SIGNED
NORATEST: An e-Health solution for a better Alzheimer's diagnosis and management
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0NORATEST project word cloud
Explore the words cloud of the NORATEST project. It provides you a very rough idea of what is the project "NORATEST" about.
Project "NORATEST" data sheet
The following table provides information about the project.
| Coordinator |
ALZOHIS
Organization address contact info |
| Coordinator Country | France [FR] |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-12-01 to 2020-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ALZOHIS | FR (PARIS) | coordinator | 50˙000.00 |
Map
Project objective
Alzheimer's disease (AD) is a major medical problem and is currently an issue of global general interest as the total number of people with dementia is projected to reach ~80M in 2030 and almost duplicating this number by 2050. The lack of an efficient and affordable solution in the AD's health care sector has motivated our company Alzohis to develop NORATEST, a very unique and innovative e-Health platform producing significant improvements, in terms of speed efficiency, in the detection of neurodegenerative diseases. By means of a novel combination of biomarkers “signatures” detectable in the blood with a state-of-the-art computer algorithm NORATEST can discriminate patients suffering AD from those healthy ones, as well as detecting other neurodegenerative diseases. Our prototype, currently at TRL6, is the first reliable non-invasive molecular diagnostic method able to detect the disease in the very early stages, offering several competitive and innovative advantages such as: Cost-effective novel technology, fast, accurate, early ddiagnosis, data privacy coupled to smart analytics, user-friendly and highly scalable and adaptable platform. Our business model is a pay-per-use combined model of charging per analysis and direct online sales. The global AD market shows great opportunities for us since it was worth €2.5 B in 2016 and is set to reach €12.6 B by 2026 (CAGR of 17.5%). Worldwide we expect a market growth in both established and in developing countries, anticipating >5M annual AD's diagnoses in the two main markets leaders based in Europe (2.5-3.5M diagnoses/year) and USA (1.5-2.5M diagnoses/year) by 2024. Our company goal is to become the reference for AD's diagnosis in Europe. We estimated that in 5 years (end of Phase 2 project), we will accumulate 360K diagnosis tests sales (revenue €54M) accounting for ~2% of the EU and USA market. We expect to hire 40 new technical and sales employees and earn ~€32M profit, with a ROI of 6.5.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NORATEST" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NORATEST" are provided by the European Opendata Portal: CORDIS opendata.